RE:ATE Insider Tradingdavgro wrote: Now that I have the Dumpster back on IGNORE we can engage in some relevant ATE discussions.
There has been a lot of discussion recently about Insider Trades. I grabbed a good chart that outlines ATE insider trades for the last 2 years. Looking only at dollar values the insider trades have been insignificant other than a $300K sell in Q1 2021. I personally see nothing positive or negative in recent ATE insider trades, or lack thereof. Moving forward my focus is entirely on the science and I am optimistic that "long-term" my investment in ATE will pay off.
Very true Davgro - you have to really pick through the noise and find what matters.
Not saying that insider trading should be ignored - but I'm saying there are ways to get answers to your burning questions here.
That being said, I see more important items to concern myself with ... once I dive a little deeper into everything Antibe ...
1. Is the P2A/B representative of what we should expect in the upcoming P2 studies?
2. Does P2 - Wisdom Teeth take some risk out of P2 Bunionectomy trial?
3. What will offset the lab time for 346 now that we have a Wisdom Teeth plan?
4. Why haven't we seen a 352 update in a very long while?
5. Why is there detail of our anti-viral on EPO and no additional updates?
6. Why haven't we filed for fast-track and what is the chance of getting break-through therapy?
7. Why is Wallace no longer the CSO and what is the significance of him going back to the lab?
8. What kind of chemistry are we expecting from the new IBD drug and will that chemistry pave the way for future drug development - if so - in what manner?
9. How is the 346 chronic hypothesis work progressing and what potential options are there for dealing with chronic?
10. Why is the AGM in September?
11.When will we get a glimpse at the commercial study for 346?
12.What is the actual addressible market size for 346 and what percentage of that market should we expect as a best-in-class drug for when you wake up in OR?
13.What are we seeing in the acquisition market and how is Big Pharma paying to own/partner at this time?
Those are the kinds of questions that matter and they are the ones that help build your understanding and your expectation for this company.
Knowing what matters sets one apart from a simple troll - IMO
: )